Hematological Malignancies also termed as blood cancers are derivative of blood cells that form cancerous cell tissues. It has been witnessed that maximum of the blood cancers begin in the marrow of the bone and affect the creation as well as the role of the blood. Stem cells there in the marrow of the bone grow into three kinds of cells known as white blood corpuscles, red blood corpuscles and blood platelets. During hematological malignancies abnormal blood cells proliferate in an uncontrolled way in the marrow of the bone. These blood cells are not capable of preventing body infections. Few of the examples of hematological malignancies are lymphoma, leukemia and myeloma. Lymphoma is a cancer caused to the part of the body immune system termed as lymph system. It is one of the chronic forms of cancer that is linked to the blood system. Its birth is due to excessive production of blood lymphocytes. Lymphoma is bifurcated into two main sub kinds namely non-Hodgkin lymphoma and Hodgkin lymphoma. Another type of cancer known as leukemia is caused due to swift proliferation and creation of abnormal white blood corpuscles in the body. Myeloma is a type of cancer caused due to abnormal division and growth of plasma tissue cells. These cells are the white blood corpuscles which protect your body from diseases & infections and provide immunity to your body by producing anti genes & antibodies in your body.
The hematological malignancies market is bifurcated depending on the availability of treatments like surgical treatment, chemotherapy and radiation therapy. Chemotherapy comprises of multi-drug combination therapy that includes drugs like cyclophosphamaide, vincristine, prednisolone, etoposide and doxorubicin. Further, new drugs such as bexarotene, romidepsin, pralatrexate and gemcitabine. Surgical treatment is primarily carried out to transplant marrow of bone or stem cell as the treatment of bone marrow has proved to be effective in treating the patients suffering from this dreaded disease of blood cancer. In case of radiation therapy, the highly powered X-rays or gamma rays are used to treat the cancerous blood cells.
The hematological malignancies market is expressed to display a balanced growth rate during the estimated time cycle of 2013 to 2020. This growth is driven by key aspects such as increasing occurrence of different diseases and widespread research & development practices executed all across the world to bring more effective drugs with new innovative formulas in hematological malignancies market.
New (drug) therapies of medical treatments like epoch chemotherapy and drugs like immunomodulatory drugs, histone deacetylase (HDAC) inhibitors and proteasome inhibitors are also expected to be introduced in the hematological malignancies market during the estimated period. These factors are expected to accelerate and emphasize the market growth rate. These factors combined with other aspects like growing awareness of disease and rising medical infrastructure adds to the growth of hematological malignancies market. Key inhibitors to the market growth of hematological malignancies market are raising costs of treatments and diagnosis.
The market research report study examines the market depending upon its market sections, key geographical locations and ongoing trends of market. The hematological malignancies market is divided into four regions based on the geographical locations, namely, region of Asia-Pacific, Zone of Europe, North American Sub Continent and rest of the world.
Sub-Continent of North America has dominated the global market due to growing visibility in frequency of patient cases afflicted by lymphoma cancers in this region and rising focus on research & development for the medical treatments by the medical authorities. Also, Asia Pacific zone and Rest of the World are the potential upcoming markets due to growing awareness about blood cancers and its ongoing treatments along with its chronic impact on the patients suffering from the disease.
Some of the key market players functioning in the hematological malignancies market are Celgene Corporation, Takeda Pharmaceutical Company Limited, Pfizer Incorporation and AbbVie Incorporation.
The market research study includes analyses of market growth drivers, market structure, market size, ongoing trends of technology, current developments, changes and innovations in technology and future market predictions. It also includes porter’s five forces analysis model, detailed profiles of key players of market, value chain analysis, competitor analysis, market share analysis, portfolio analysis, competitor analysis , strategic analysis , supply chain analysis and SWOT analysis of the market segments displayed by using the graphical tools of data representation such as diagrams, flow charts, diagrams , charts and tables.
